Navigation Links
Mylan Announces Move to NASDAQ Stock Market
Date:12/12/2008

PITTSBURGH, Dec. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it will move its stock exchange listing to The NASDAQ Stock Market, an exchange of The NASDAQ OMX Group Inc. (Nasdaq: NDAQ), from The New York Stock Exchange (NYSE) effective Dec. 29. The company will be listed on the NASDAQ Global Select Market, and its common stock will continue to trade under the "MYL" ticker symbol.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Notwithstanding the obvious financial benefits that NASDAQ offers, the decision to switch Mylan's listing was also driven by the fact that for quite some time a greater portion of our total trading volume was already crossing on NASDAQ trading facilities. This decision, we believe, will further enhance Mylan's overall needs and efficiencies."

Mylan's mandatory convertible preferred stock and 1.25% convertible notes also will move to NASDAQ with the ticker symbols "MYLNP" and "MYLNG," respectively.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
2. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
3. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
6. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
7. Mylan to Offer $400 Million in Cash Convertible Notes
8. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
9. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: